Clinical trials: Temozolomide, completed
Glioblastoma
Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults
The main goal of this study is to evaluate and to determine the dose of a highly accurate irradiation (allowing to increase the dose delivered while restricting the risk of complication) in association with temozolomide.
- Trial name
- SIB-IMRT (NCT01043536)
- Testing
- radiotherapy, temozolomide
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Georges Francois Leclerc
Leukemia
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098436
- Testing
- laromustine, temozolomide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vion Pharmaceuticals
Neuroblastoma
Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
This is a safety / feasibility trial evaluating the combination of a humanized anti-GD2 antibody (HU14.18K322A) manufactured at the Children's GMP, LLC at St.
- Trial name
- NCT01576692
- Testing
- Humanized anti-GD2 antibody, Chemotherapy, Cytokines
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- St. Jude Children's Research Hospital
Recurrent Melanoma, Stage IV Melanoma
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
This phase II trial is studying how well giving temozolomide together with thalidomide works in treating patients with brain metastases secondary to melanoma.
- Conditions
- Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
- Trial name
- NCT00072163
- Testing
- temozolomide, thalidomide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Oligodendroglioma; Oligoastrocytoma
Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis
The first-line treatment of anaplastic oligodendrogliomas, radiotherapy exclusive or combined with PCV, will be defined by the pending results of phase III of the EORTC.
- Trial name
- TEMOBIC (NCT04755023)
- Testing
- Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide
- Where
- France
- Volunteers
- 53 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Malignant Neoplasms of Brain
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, increase the number of white blood cells and platelets found in bone…
- Trial name
- ACTIVATe (NCT00643097)
- Testing
- PEP-3 vaccine, sargramostim, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- John Sampson
Brain and Central Nervous System Tumors
Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006474
- Testing
- O6-benzylguanine, temozolomide, conventional surgery
- Where
- United States
- Sponsor
- Duke University
Gastrointestinal Stromal Tumor
S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have unresectable…
- Trial name
- NCT00005597
- Testing
- temozolomide
- Where
- 106 sites in United States
- Volunteers
- 25 people
- Sponsor
- SWOG Cancer Research Network
Brain and Central Nervous System Tumors
Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00033280
- Testing
- temozolomide, neoadjuvant therapy, radiation therapy
- Where
- 39 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Radiation Therapy Oncology Group
Advanced Rectal Cancer
Preoperative CRT With Capecitabine ± Temozolomide in Patients With LARC
This is a prospective biomarker-stratified, randomised phase II study of preoperative CRT with temozolomide plus capecitabine in patients with locally advanced rectal cancer.
- Trial name
- NCT03156036
- Testing
- Capecitabine plus temozolomide VS Capecitabine
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Asan Medical Center
Anaplastic Glioma of Brain, Glioblastoma Multiforme
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
The goal of this clinical research study is to learn if the combination of 6-Thioguanine, Xeloda (capecitabine), and Celebrex (celecoxib) with Temodar (temozolomide) or Lomustine (CCNU) is effective in the treatment of recurrent…
- Conditions
- Anaplastic Glioma of Brain, Glioblastoma Multiforme, Brain Cancer
- Trial name
- NCT00504660
- Testing
- Capecitabine, Celecoxib (Celebrex), Temozolomide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma, Gliosarcoma
Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas
Primary objective- To determine efficacy of Avastin, 10 mg/kg every other week, in combination with standard 5-day temozolomide in terms of response rate.
- Trial name
- NCT00612339
- Testing
- Avastin and Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Duke University
Glioblastoma
Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma
Glioblastoma (GBM) is the most frequent primary brain tumor and the brain tumor with the poorest prognosis. The current treatment relies on surgical resection of gross tumor followed by radiochemotherapy and adjuvant therapy with…
- Trial name
- UCPVax-Glio (NCT04280848)
- Testing
- UCPVax, Temozolomide
- Where
- 5 sites in France
- Volunteers
- 67 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Glioblastoma Multiforme
Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide
The long term goal of this research is to establish whether NPC sparing RT techniques improve neurocognitive outcomes compared to conventional RT for brain tumors.
- Trial name
- NCT01478854
- Testing
- Radiation, Chemotherapy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Newly Diagnosed Glioblastoma Multiforme
Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme
The purpose of this study is to test the safety and effects of a combination of a study drug, Lapatinib, plus the administration of standard radiation therapy and an FDA approved drug Temozolomide (chemotherapy agent) in patients…
- Trial name
- NCT01591577
- Testing
- Lapatinib/Temozolomide/radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Melanoma
Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01005472
- Testing
- sunitinib malate, temozolomide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adult Glioblastoma, Adult Gliosarcoma
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
This randomized phase II trial is studying the side effects and how well giving bevacizumab together with irinotecan or temozolomide works in treating patients with recurrent or refractory glioblastoma multiforme or gliosarcoma.
- Conditions
- Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00433381
- Testing
- Bevacizumab, Irinotecan Hydrochloride, Temozolomide
- Where
- 93 sites in United States
- Volunteers
- 123 people
- Sponsor
- National Cancer Institute (NCI)
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Cilengitide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00085254
- Testing
- cilengitide, temozolomide, radiation therapy
- Where
- 8 sites in United States
- Volunteers
- 112 people
- Sponsor
- National Cancer Institute (NCI)
Tumors
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
The purpose of the study is to assess the safety and establish the maximum tolerated dose (MTD) of the combination of BSI-201 with chemotherapeutic regimens in adult subjects with histologically or cytologically documented…
- Trial name
- NCT00422682
- Testing
- bsi-201 + topotecan, bsi-201 + temozolomide, bsi-201 + gemcitabine
- Where
- 6 sites in United States
- Volunteers
- 136 people
- Sponsor
- Sanofi